Marijuana Use & Asthma: Risks and Considerations (AAN)

Price: FREE for members and non-members

Session recorded on January 30, 2025
Speaker: Anil Nanda, MD, FACAAI

As cannabis use becomes legal in more states, many people are seeking it out for medical and recreational use. Despite the increasing prevalence of cannabis use, there is limited understanding among healthcare providers about its impact on asthma and respiratory health, leading to gaps in patient education and management. Dr. Nanda will explain the effects of cannabis smoking on asthma management, discuss asthma management plans to include cannabis-related risk assessments, and share ways to counsel patients about the risks.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity learners should be able to:
1.    Explain the respiratory effects of cannabis smoking and its implications for asthma management.
2.    Adapt asthma management plans to include cannabis-related risk assessments. 
3.    Integrate strategies to counsel patients about the risks associated with cannabis use related to asthma management.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
02/04/2025
Course expires: 
12/31/2026
Rating: 
0

All identified relevant financial relationships with ineligible companies have been mitigated.

Speaker:
Anil Nanda, MD, FACAAI
No relevant finanical relationships with ineligible companies to disclose

Moderator:
Lynda Mitchell, MA, CAE, Allergy Asthma Network (AAN)
No relevant finanical relationships with ineligible companies to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.